US2018127506A1PendingUtilityA1

Dac hyp compositions and methods

Assignee: ABBVIE BIOTHERAPEUTICS INCPriority: May 27, 2011Filed: Oct 4, 2017Published: May 10, 2018

Est. expiryMay 27, 2031(~4.9 yrs left)· nominal 20-yr term from priority

Inventors:Taymar E. Hartman Paul W. Sauer John E. Burky Mark C. Wesson Ping Huang Thomas J. Robinson Braeden D. Partridge J. Yun Tso

A61P 37/02A61P 37/06A61P 43/00A61P 27/02A61P 25/28C07K 2317/73C07K 2317/41C07K 2317/92C07K 2317/732A61K 2039/505C07K 2317/76A61L 2/18A61K 38/215C07K 2317/94C12N 2500/95A61K 39/3955C12N 2511/00C12N 2510/02C07K 2317/24C07K 16/2866C07K 2317/14A61P 25/00C07K 2317/56C12N 2510/04Y02A50/30

PatentIndex Score

Cited by

References

Claims

Abstract

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.

Claims

exact text as granted — not AI-modified

1 .- 20 . (canceled) 
     
     
         21 . A medium which is a basal medium PFBM2 or a feed medium PFFM3. 
     
     
         22 .- 33 . (canceled)

Join the waitlist — get patent alerts

Track US2018127506A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.